The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response
Open Access
- 1 May 2022
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 36 (9-10), 582-600
- https://doi.org/10.1101/gad.349321.121
Abstract
One of the mechanisms by which cancer cells acquire hyperinvasive and migratory properties with progressive loss of epithelial markers is the epithelial-to-mesenchymal transition (EMT). We have previously reported that in different cancer types, including nonsmall cell lung cancer (NSCLC), the microRNA-183/96/182 cluster (m96cl) is highly repressed in cells that have undergone EMT. In the present study, we used a novel conditional m96cl mouse to establish that loss of m96cl accelerated the growth of Kras mutant autochthonous lung adenocarcinomas. In contrast, ectopic expression of the m96cl in NSCLC cells results in a robust suppression of migration and invasion in vitro, and tumor growth and metastasis in vivo. Detailed immune profiling of the tumors revealed a significant enrichment of activated CD8+ cytotoxic T lymphocytes (CD8+ CTLs) in m96cl-expressing tumors, and m96cl-mediated suppression of tumor growth and metastasis was CD8+ CTL-dependent. Using coculture assays with naïve immune cells, we show that m96cl expression drives paracrine stimulation of CD8+ CTL proliferation and function. Using tumor microenvironment-associated gene expression profiling, we identified that m96cl elevates the interleukin-2 (IL2) signaling pathway and results in increased IL2-mediated paracrine stimulation of CD8+ CTLs. Furthermore, we identified that the m96cl modulates the expression of IL2 in cancer cells by regulating the expression of transcriptional repressors Foxf2 and Zeb1, and thereby alters the levels of secreted IL2 in the tumor microenvironment. Last, we show that in vivo depletion of IL2 abrogates m96cl-mediated activation of CD8+ CTLs and results in loss of metastatic suppression. Therefore, we have identified a novel mechanistic role of the m96cl in the suppression of lung cancer growth and metastasis by inducing an IL2-mediated systemic CD8+ CTL immune response.Keywords
Funding Information
- CCSG
- National Institutes of Health (CA125123)
- Cancer Prevention and Research Institute of Texas (RP170067)
- NIH
- CPRIT-Multi-Investigator Research Award (RP160652-P3)
- Rexanna's Foundation for Fighting Lung Cancer
This publication has 57 references indexed in Scilit:
- ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expressionJCI Insight, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expressionGenes & Development, 2009
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictionsRNA, 2008
- The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2Online Journal of Public Health Informatics, 2008
- A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cellsEMBO Reports, 2008
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.Proceedings of the National Academy of Sciences of the United States of America, 1993